Bristol-Myers Squibb: Sofinnova Partners exceeds target with 165M Biotech Acceleration Fund, Europe's largest, with strong Pharma support

Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova's biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. The post Sofinnova Partners exceeds target with €165M Biotech Acceleration Fund, Europe's largest, with strong Pharma support appeared first on emeastartups.